Ipamorelin Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: ipamorelin human pharmacokinetics

Growth Signal Research peptide Lyophilized verified

Also known as: IPA

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

5 mg, 10 mg

Calculator

Preset available

Storage

Lyophilized: store at -20 deg C. After reconstitution: refrigerate 2-8 deg C; verify beyond-use timing against source COA.

Solubility

Salt and supplier formulation dependent

Catalog Description

Ipamorelin is a selective growth-hormone secretagogue (GHS-R1a agonist). Comparative pharmacology research shows that unlike GHRP-2 and hexarelin - which also activate non-GHS-R1a/CRF pathways and produce measurable ACTH/cortisol release similar in magnitude to human CRH - ipamorelin stimulates GH release at levels comparable to GHRP-6 while producing no statistically significant elevation in ACTH, cortisol, or prolactin. This selectivity profile is the primary reason it is commonly paired with a GHRH analog (e.g., CJC-1295) in GH-axis research rather than used alone.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

Terminal half-life about 2 hours in healthy volunteers

Onset

GH peaked at about 0.67 hours after the study infusion

Administration Routes (Research)

IV in human PK-PD researchSC use is unapproved community practice

Reported Research Effects

Selective GH release via GHS-R1a agonism
No significant cortisol/ACTH/prolactin elevation (unlike GHRP-2/hexarelin)
Commonly combined with GHRH analogs for synergistic pulsatile GH release

Reported Research Side Effects

GH and IGF-1 elevation
Headache or flushing
Glucose effects
Long-term human safety is unknown

Data source: Primary human pharmacokinetic-pharmacodynamic study

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

4.21-140.45 nmol/kg over 15 minutes as ascending infusion rates [IV; Single-dose PK-PD study; Once]Source: PMID 10496658
No validated chronic SC protocol is established [SC; Not established; Not established]Source: evidence gap

Research Interactions

Flagged Avoid / Caution Combinations (Research)

Other GH secretagogues
Active malignancy or conditions where increased GH or IGF-1 signaling is undesirable

Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.

Research Notes

Five repeated or unsupported 100-300 mcg SC schedules were removed. The primary human PK study used short IV infusions, not a 14-day three-times-daily SC regimen.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

Ipamorelin human PK-PD modeling study — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/10496658/

Ipamorelin human pharmacology study — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/9849822/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.